Killer virus turned against childhood brain cancer
NCT ID NCT03911388
First seen Feb 18, 2026 · Last updated Jun 23, 2026 · Updated 21 times
Summary
This early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a low dose of radiation to help the virus work better. The goal is to see if the treatment is safe and tolerable, not yet to prove it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's of Alabama
ACTIVE_NOT_RECRUITINGBirmingham, Alabama, 35233, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Louis Children's Hospital
ACTIVE_NOT_RECRUITINGSt Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
G207 (an engineered herpes simplex virus)
What this could lead to
If it works, this could point toward a new treatment option for children with hard-to-treat brain tumors that have come back after standard therapy.
What could go wrong
This is a very early phase 1 trial with only 24 children, focused on safety. The virus may not shrink tumors, and there are risks of serious side effects from the virus or the added radiation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.